Serum lipid and bone metabolism effects of Toremifene vs. Letrozole as adjuvant therapy for postmenopausal early breast cancer patients: results of a multicenter open randomized study

Tadahiko Shien, Hiroyoshi Doihara, Nobuaki Sato, Keisei Anan, Kansei Komaki, Keisuke Miyauchi, Yasuhiro Yanagita, Tomomi Fujisawa, Shoshu Mitsuyama, Chizuko Kanbayashi, Mikihiro Kusama, Morihiko Kimura, Hiromitsu Jinno, Muneaki Sano, Tadashi Ikeda

Research output: Contribution to journalArticle

Abstract

A prospective randomized phase II trial was conducted to evaluate the time course effects of toremifene (TOR) and letrozole (LET), as adjuvant hormone therapy, on serum lipid profiles and bone metabolism in estrogen receptor (ER)-positive, postmenopausal breast cancer patients.Fifty-four postmenopausal breast cancer patients [ER positive, HER2 negative, T1–2, node metastases (n = 0–3), M0] who had undergone curative resection were enrolled. They were randomized to receive either TOR 40 mg/day or LET 2.5 mg/day as adjuvant hormone therapy. Serum lipids and bone markers were measured prior to, and again at 6, 12, and 24 months after initiation of treatment. Changes in serum lipids and bone markers were compared. Serum levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) were decreased compared with the baseline values at 6 months in 6.5 and 14.0% of patients, respectively, receiving TOR. Lipid levels did not change in patients administered LET. Significant differences were observed in TC and LDL-C between the two groups at 12 and 24 months. In the TOR group, serum bone-specific alkaline phosphatase (BAP) was decreased by 25.0% at 12 months, and serum cross-linked N-telopeptide of type-I collagen (NTx) was decreased by 13.6% at 6 months, and these reductions were maintained for at least 24 months. In contrast, in the LET group, serum BAP did not change and NTx was increased by 16.0% at 6 months and by 18.6% at 24 months, as compared with the baseline.TOR and LET exert different effects on serum lipid profiles and bone metabolism markers. The effects of TOR, as adjuvant hormone therapy, on both lipids and bone metabolism in postmenopausal breast cancer patients are superior to those of LET.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalCancer Chemotherapy and Pharmacology
DOIs
Publication statusAccepted/In press - Dec 1 2017

Fingerprint

letrozole
Toremifene
Lipid Metabolism
Metabolism
Bone
Breast Neoplasms
Lipids
Bone and Bones
Serum
Cholesterol
Hormones
Estrogen Receptors
LDL Cholesterol
Therapeutics
Alkaline Phosphatase
Collagen Type I

Keywords

  • Adjuvant therapy
  • Bone metabolism
  • Endocrine therapy
  • Lipid metabolism
  • Postmenopausal

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Serum lipid and bone metabolism effects of Toremifene vs. Letrozole as adjuvant therapy for postmenopausal early breast cancer patients : results of a multicenter open randomized study. / Shien, Tadahiko; Doihara, Hiroyoshi; Sato, Nobuaki; Anan, Keisei; Komaki, Kansei; Miyauchi, Keisuke; Yanagita, Yasuhiro; Fujisawa, Tomomi; Mitsuyama, Shoshu; Kanbayashi, Chizuko; Kusama, Mikihiro; Kimura, Morihiko; Jinno, Hiromitsu; Sano, Muneaki; Ikeda, Tadashi.

In: Cancer Chemotherapy and Pharmacology, 01.12.2017, p. 1-7.

Research output: Contribution to journalArticle

Shien, Tadahiko ; Doihara, Hiroyoshi ; Sato, Nobuaki ; Anan, Keisei ; Komaki, Kansei ; Miyauchi, Keisuke ; Yanagita, Yasuhiro ; Fujisawa, Tomomi ; Mitsuyama, Shoshu ; Kanbayashi, Chizuko ; Kusama, Mikihiro ; Kimura, Morihiko ; Jinno, Hiromitsu ; Sano, Muneaki ; Ikeda, Tadashi. / Serum lipid and bone metabolism effects of Toremifene vs. Letrozole as adjuvant therapy for postmenopausal early breast cancer patients : results of a multicenter open randomized study. In: Cancer Chemotherapy and Pharmacology. 2017 ; pp. 1-7.
@article{b83d0de200964356aee651da61cf2854,
title = "Serum lipid and bone metabolism effects of Toremifene vs. Letrozole as adjuvant therapy for postmenopausal early breast cancer patients: results of a multicenter open randomized study",
abstract = "A prospective randomized phase II trial was conducted to evaluate the time course effects of toremifene (TOR) and letrozole (LET), as adjuvant hormone therapy, on serum lipid profiles and bone metabolism in estrogen receptor (ER)-positive, postmenopausal breast cancer patients.Fifty-four postmenopausal breast cancer patients [ER positive, HER2 negative, T1–2, node metastases (n = 0–3), M0] who had undergone curative resection were enrolled. They were randomized to receive either TOR 40 mg/day or LET 2.5 mg/day as adjuvant hormone therapy. Serum lipids and bone markers were measured prior to, and again at 6, 12, and 24 months after initiation of treatment. Changes in serum lipids and bone markers were compared. Serum levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) were decreased compared with the baseline values at 6 months in 6.5 and 14.0{\%} of patients, respectively, receiving TOR. Lipid levels did not change in patients administered LET. Significant differences were observed in TC and LDL-C between the two groups at 12 and 24 months. In the TOR group, serum bone-specific alkaline phosphatase (BAP) was decreased by 25.0{\%} at 12 months, and serum cross-linked N-telopeptide of type-I collagen (NTx) was decreased by 13.6{\%} at 6 months, and these reductions were maintained for at least 24 months. In contrast, in the LET group, serum BAP did not change and NTx was increased by 16.0{\%} at 6 months and by 18.6{\%} at 24 months, as compared with the baseline.TOR and LET exert different effects on serum lipid profiles and bone metabolism markers. The effects of TOR, as adjuvant hormone therapy, on both lipids and bone metabolism in postmenopausal breast cancer patients are superior to those of LET.",
keywords = "Adjuvant therapy, Bone metabolism, Endocrine therapy, Lipid metabolism, Postmenopausal",
author = "Tadahiko Shien and Hiroyoshi Doihara and Nobuaki Sato and Keisei Anan and Kansei Komaki and Keisuke Miyauchi and Yasuhiro Yanagita and Tomomi Fujisawa and Shoshu Mitsuyama and Chizuko Kanbayashi and Mikihiro Kusama and Morihiko Kimura and Hiromitsu Jinno and Muneaki Sano and Tadashi Ikeda",
year = "2017",
month = "12",
day = "1",
doi = "10.1007/s00280-017-3491-6",
language = "English",
pages = "1--7",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Serum lipid and bone metabolism effects of Toremifene vs. Letrozole as adjuvant therapy for postmenopausal early breast cancer patients

T2 - results of a multicenter open randomized study

AU - Shien, Tadahiko

AU - Doihara, Hiroyoshi

AU - Sato, Nobuaki

AU - Anan, Keisei

AU - Komaki, Kansei

AU - Miyauchi, Keisuke

AU - Yanagita, Yasuhiro

AU - Fujisawa, Tomomi

AU - Mitsuyama, Shoshu

AU - Kanbayashi, Chizuko

AU - Kusama, Mikihiro

AU - Kimura, Morihiko

AU - Jinno, Hiromitsu

AU - Sano, Muneaki

AU - Ikeda, Tadashi

PY - 2017/12/1

Y1 - 2017/12/1

N2 - A prospective randomized phase II trial was conducted to evaluate the time course effects of toremifene (TOR) and letrozole (LET), as adjuvant hormone therapy, on serum lipid profiles and bone metabolism in estrogen receptor (ER)-positive, postmenopausal breast cancer patients.Fifty-four postmenopausal breast cancer patients [ER positive, HER2 negative, T1–2, node metastases (n = 0–3), M0] who had undergone curative resection were enrolled. They were randomized to receive either TOR 40 mg/day or LET 2.5 mg/day as adjuvant hormone therapy. Serum lipids and bone markers were measured prior to, and again at 6, 12, and 24 months after initiation of treatment. Changes in serum lipids and bone markers were compared. Serum levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) were decreased compared with the baseline values at 6 months in 6.5 and 14.0% of patients, respectively, receiving TOR. Lipid levels did not change in patients administered LET. Significant differences were observed in TC and LDL-C between the two groups at 12 and 24 months. In the TOR group, serum bone-specific alkaline phosphatase (BAP) was decreased by 25.0% at 12 months, and serum cross-linked N-telopeptide of type-I collagen (NTx) was decreased by 13.6% at 6 months, and these reductions were maintained for at least 24 months. In contrast, in the LET group, serum BAP did not change and NTx was increased by 16.0% at 6 months and by 18.6% at 24 months, as compared with the baseline.TOR and LET exert different effects on serum lipid profiles and bone metabolism markers. The effects of TOR, as adjuvant hormone therapy, on both lipids and bone metabolism in postmenopausal breast cancer patients are superior to those of LET.

AB - A prospective randomized phase II trial was conducted to evaluate the time course effects of toremifene (TOR) and letrozole (LET), as adjuvant hormone therapy, on serum lipid profiles and bone metabolism in estrogen receptor (ER)-positive, postmenopausal breast cancer patients.Fifty-four postmenopausal breast cancer patients [ER positive, HER2 negative, T1–2, node metastases (n = 0–3), M0] who had undergone curative resection were enrolled. They were randomized to receive either TOR 40 mg/day or LET 2.5 mg/day as adjuvant hormone therapy. Serum lipids and bone markers were measured prior to, and again at 6, 12, and 24 months after initiation of treatment. Changes in serum lipids and bone markers were compared. Serum levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) were decreased compared with the baseline values at 6 months in 6.5 and 14.0% of patients, respectively, receiving TOR. Lipid levels did not change in patients administered LET. Significant differences were observed in TC and LDL-C between the two groups at 12 and 24 months. In the TOR group, serum bone-specific alkaline phosphatase (BAP) was decreased by 25.0% at 12 months, and serum cross-linked N-telopeptide of type-I collagen (NTx) was decreased by 13.6% at 6 months, and these reductions were maintained for at least 24 months. In contrast, in the LET group, serum BAP did not change and NTx was increased by 16.0% at 6 months and by 18.6% at 24 months, as compared with the baseline.TOR and LET exert different effects on serum lipid profiles and bone metabolism markers. The effects of TOR, as adjuvant hormone therapy, on both lipids and bone metabolism in postmenopausal breast cancer patients are superior to those of LET.

KW - Adjuvant therapy

KW - Bone metabolism

KW - Endocrine therapy

KW - Lipid metabolism

KW - Postmenopausal

UR - http://www.scopus.com/inward/record.url?scp=85035759317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035759317&partnerID=8YFLogxK

U2 - 10.1007/s00280-017-3491-6

DO - 10.1007/s00280-017-3491-6

M3 - Article

C2 - 29196963

AN - SCOPUS:85035759317

SP - 1

EP - 7

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

ER -